Stoke Therapeutics (STOK) Net Cash Flow Growth (3y) (2021 - 2026)
Stoke Therapeutics (STOK) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 32.17% |
| 10 | Stoke Therapeutics | 1.86 Bn | 1.52 Bn | - | -1.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03% |
| Dec 31, 2025 | 72.83% |
| Sep 30, 2025 | -33.84% |
| Jun 30, 2025 | -119.65% |
| Mar 31, 2025 | 64.06% |
| Dec 31, 2024 | -71.94% |
| Sep 30, 2024 | -30.54% |
| Jun 30, 2024 | 29.09% |
| Mar 31, 2024 | 13.39% |
| Dec 31, 2023 | -75.18% |
| Sep 30, 2023 | 41.62% |
| Jun 30, 2023 | 29.74% |
| Mar 31, 2023 | 106.97% |
| Dec 31, 2022 | 26.31% |
| Sep 30, 2022 | 88.89% |
| Jun 30, 2022 | -28.33% |
| Mar 31, 2022 | -108.67% |
| Dec 31, 2021 | -27.03% |
| Sep 30, 2021 | -58.60% |